Martingale Asset Management’s Immunovant IMVT Stock Holding History

Martingale Asset Management’s Portfolio IMVT Stock Details IMVT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$717K	Hold	18,607	–	–	0.02%	591
2026 Q1	$462K	Buy	+18,607	New	+$482K	0.01%	659
2023 Q2	–	Sell	-21,605	Closed	-$335K	–	841
2023 Q1	$335K	Sell	21,605 -18,105	-46%	-$314K	0.01%	691
2022 Q4	$705K	Sell	39,710 -30,428	-43%	-$383K	0.01%	554
2022 Q3	$392K	Buy	70,138 +74	+0.1%	+$362	0.01%	665
2022 Q2	$274K	Buy	70,064 +13	+0%	+$56	0.01%	751
2022 Q1	$386K	Buy	70,051 +8,200	+13%	+$51.1K	0.01%	685
2021 Q4	$527K	Buy	61,851 +2,900	+5%	+$23.9K	0.01%	636
2021 Q3	$513K	Buy	58,951 +39,430	+202%	+$356K	0.01%	666
2021 Q2	$207K	Buy	+19,521	New	+$273K	﹤0.01%	799

Other funds holding IMVT

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Martingale Asset Management's IMVT Position: Q2 2026 in Review

Martingale Asset Management held its Immunovant (IMVT) position steady in Q2 2026 at 18,607 shares worth $717K. The position accounts for 0.02% of the portfolio, ranked #591.

Martingale Asset Management first reported a position in IMVT in Q2 2021 and has held it in 10 quarters since. 226 funds tracked by Wall St. Rank hold IMVT as of Q2 2026.

Martingale Asset Management held 18,607 shares of Immunovant worth $717K as of Q2 2026.
Martingale Asset Management left its Immunovant share count unchanged in Q2 2026.
Immunovant made up 0.02% of Martingale Asset Management's portfolio in Q2 2026, its #591 holding.
Martingale Asset Management first reported a position in Immunovant in Q2 2021 and has held it in 10 quarters since.
226 funds tracked by Wall St. Rank held Immunovant as of Q2 2026.

Based on Martingale Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.